Acadian Asset Management
ONCT

Acadian Asset Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Acadian Asset Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,829
Closed – – 1863
2024
Q4 		$0 Hold
1,829
– – ﹤0.01% 2274
2024
Q3 		$2K Hold
1,829
– – ﹤0.01% 2045
2024
Q2 		$13K Sell
1,829
-120
-6% -$1.03K ﹤0.01% 1694
2024
Q1 		$17K Sell
1,949
-1,690
-46% -$14.9K ﹤0.01% 1499
2023
Q4 		$38K Hold
3,639
– – ﹤0.01% 1494
2023
Q3 		$21K Sell
3,639
-1,759
-33% -$12.4K ﹤0.01% 1542
2023
Q2 		$36K Sell
5,398
-2,883
-35% -$19K ﹤0.01% 1567
2023
Q1 		$128K Sell
8,281
-2,824
-25% -$55.6K ﹤0.01% 1345
2022
Q4 		$220K Buy
11,105
+1,437
+15% +$28.6K ﹤0.01% 1262
2022
Q3 		$171K Buy
9,668
+6,329
+190% +$136K ﹤0.01% 1251
2022
Q2 		$74K Buy
+3,339
New +$74.4K ﹤0.01% 1420

Acadian Asset Management's ONCT Position: Q1 2025 in Review

Acadian Asset Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2025, closing a stake of 1,829 shares.

Acadian Asset Management first reported a position in ONCT in Q2 2022 and held it in 11 quarters. The position peaked at $220K in Q4 2022. 0 funds tracked by Wall St. Rank hold ONCT as of Q1 2025.

  • Acadian Asset Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Acadian Asset Management sold 1,829 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2025.
  • Acadian Asset Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2022 and held it in 11 quarters.
  • Acadian Asset Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $220K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Acadian Asset Management's 13F filing for Q1 2025, filed 21 May 2025.